Cracking one of medicine’s newest mysteries VEXAS syndrome is an adult-onset autoinflammatory disorder that was first identified in 2020. Caused by somatic mutations in the UBA1 gene, it can present with a wide spectrum of clinical manifestations. Dr. Peter Grayson, one of the researchers involved from the beginning, takes us through the story so far, from its discovery to the defining clinical features, current treatment strategies, and future hopes.
May 29, 2026•33 min•Ep. 27
How does the air we breathe affect cardiovascular health? Around one in five cardiovascular deaths are attributable to environmental stressors, yet these are often overlooked. Air pollution is perhaps the most prevalent, but how does it affect cardiovascular health? Dr. Anusha Seneviratne elaborates on the mechanisms, epidemiological evidence, and preventive measures.
Mar 05, 2026•20 min•Ep. 26
The next frontier in cancer treatment? Recently there has been a renewed interest in the prospect of therapeutic cancer vaccines. But what exactly does it mean to vaccinate against cancer, where are vaccines showing the most promise, and what are the challenges of making such vaccines a reality? Dr. Elias Sayour answers these questions and more in this episode.
Jan 30, 2026•35 min•Ep. 25
Advancing patient care In this special edition of Medicine Matters , we're joined by Dr Gregory Lim, Claire Greenhill, and Sarah Onuora, Chief Editors of Nature Reviews Cardiology, Endocrinology, and Rheumatology, for a look back at the advances in their specialties in 2025. Find out what caught their attention and why, and what they're looking forward to in 2026.
Dec 16, 2025•24 min•Ep. 24
Clinical recommendations for diagnosis and management Around 10 to 20% of people will complain of dysphagia during their lifetime but uncertainty remains about optimal diagnostic work-up and management. Prof. Edoardo Savarino takes us through the highlights of the updated UEG and ESNM dysphagia guidelines and the difference they could make to patient outcomes.
Nov 19, 2025•28 min•Ep. 23
Marking a major milestone in chronic myeloid leukemia treatment Tyrosine kinase inhibitors have transformed the treatment of chronic myeloid leukemia, a condition that had limited therapeutic options before. In this 25th year since the first phase 2 trials of the first TKI, we speak to a researcher and clinician who has been involved since the early days. Dr. Jorge Cortes shares his experience and talks about the impact of these drugs, not only in the treatment of CML but also more widely....
Nov 05, 2025•27 min•Ep. 22
Newcomer PACAP could make the difference in migraine control Anti-CGRP therapy has dramatically improved migraine treatment for many patients since its introduction in 2018. However, 30–40% of patients do not respond adequately to these drugs. Prof. Messoud Ashina talks to us about PACAP and why targeting this pathway could offer a new future option for such patients.
Aug 28, 2025•21 min•Ep. 21
Could a world first vaccination program help to prevent the rise of antibiotic resistant cases? Dr. Hamish Mohammed discusses the rollout of the world’s first vaccination program against gonorrhea.
Aug 14, 2025•24 min•Ep. 20
From diabetes to obesity and beyond In 2005 the US FDA approved the first GLP-1 medicine for type 2 diabetes, marking the start of a remarkable journey that goes beyond the stimulation of insulin secretion. Prof. Daniel Drucker gives us a fascinating insight into the early work on GLP-1 and discusses how these medicines are impacting the lives of people with diabetes and obesity, covering what's known about how they work, treatment duration, side effects, and the role of bariatric surgery, plus ...
May 20, 2025•41 min•Ep. 19
What can we do to reduce mounting myopia prevalence? Global prevalence of myopia in children and adolescents is set to reach 40% by 2050, exceeding 740 million cases. Reducing incidence and slowing progression is essential, as myopia is linked to sight-threatening complications like retinal detachment, myopic macular degeneration, and glaucoma. Dr. Annegret Dahlmann-Noor explores the reasons behind this increase and what we can do to halt the trend.
Apr 15, 2025•30 min•Ep. 18
Why are disease-modifying treatments for osteoarthritis such a difficult proposition? "Current treatments for osteoarthritis mostly provide symptomatic relief, and so disease-modifying drugs that target the underlying structural damage would be a game changer. But despite multiple attempts, no DMOAD is yet approved for clinical use. Prof. Ali Mobasheri takes us through the main challenges, the work being done to address them to make these so-called utopia drugs a reality, and other advances that...
Mar 28, 2025•27 min•Ep. 17
Normalizing sexual wellbeing throughout adulthood Roughly 50% of women over 50 experience sexual dysfunction, yet fewer than 20% report it to their doctor, thinking these changes are 'just part of aging'. As doctors, we should be helping women lead sexually healthy and fulfilling lives as they age. Prof Holly Thomas tells us how.
Feb 27, 2025•30 min•Ep. 16
POSITIVEly reassuring results from a clinical trial The POSITIVE trial previously showed that women with breast cancer can safely interrupt endocrine therapy in order to become pregnant. But what about breastfeeding - is that possible and safe for the mother and baby? Women can take heart from the latest findings, says Dr. Cristina Saura, as she takes us through these important clinical updates.
Jan 23, 2025•18 min•Ep. 15
Can we define Alzheimer's disease as a purely biological entity? Blood-based biomarkers are set to make biological assessment of Alzheimer's disease much quicker and more accessible than has been possible with imaging and CSF biomarkers. Does this mean the disease now be defined as a purely biological entity? Dr. Nicolas Villain outlines why it is still so important to consider both clinical symptoms and biological findings when making a diagnosis.
Dec 12, 2024•18 min•Ep. 14
Welcoming a new name and a new treatment Metabolic dysfunction-associated liver disease is a significant healthcare concern and burden. Until recently there was no approved pharmacologic treatment for the more serious form of the disease, metabolic dysfunction-associated steatohepatitis. In this wide-ranging conversation, Prof. Vlad Ratziu explains the rationale behind the recently updated subclassification and nomenclature for steatotic liver disease, puts the therapeutic advance of resmetirom ...
Aug 14, 2024•37 min•Ep. 13
Is the new global definition helpful? Since publication of the Berlin criteria for ARDS in 2012, several developments have prompted the need for an update. Last year, an international group of experts rose to the challenge. But is the new definition necessary and will it have an impact on clinical practice? Prof. Giacomo Grasselli shares his thoughts.
Jul 05, 2024•16 min•Ep. 12
The essentials of individualised rehab programmes for elderly patients with CVD and frailty Nearly half of adults over the age of 65 have some degree of frailty, and over two-thirds have cardiac disease. Dr Eduard Shantsila discusses the importance of individualised rehabilitation programmes in these patients, to reduce morbidity and mortality, and improve quality of life. For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register...
May 24, 2024•19 min•Ep. 11
Reducing the burden of type 1 diabetes Despite many recent advances in its management, type 1 diabetes remains a burden for those living with the condition. Prof Chantal Mathieu explains the progress being made with disease-modifying therapy for type 1 diabetes and how it has the potential to transform the current treatment landscape. For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates....
Feb 29, 2024•35 min•Ep. 10
How do nutrition, supplements and antibiotics impact patient outcomes? Recent research suggests that the gut microbiome could be an important modulator of response to CAR T-cell therapy in patients with hematologic cancers. Prof. Marion Subklewe takes us through the latest evidence, highlighting the impact of antibiotics, nutrition, and dietary supplements, and discusses how to devise interventions to improve patient outcomes. For more on how Springer Medicine can tailor medical education to mee...
Feb 14, 2024•20 min•Ep. 9
Using deep learning to predict clinical outcomes after stroke About 50% of stroke patients have an unfavorable outcome. Predicting outcome is challenging but is key to understanding how best to treat patients. Prof. Susanne Wegener discusses her team’s work to develop deep learning models that outperform neurologists when predicting outcome based on imaging data alone or in combination with clinical data. For more on how Springer Medicine can tailor medical education to meet your needs, head to ...
Jan 03, 2024•15 min•Ep. 8
Cementing the role of adjuvant osimertinib in NSCLC The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC. We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial. For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine...
Dec 06, 2023•18 min•Ep. 7
The new normal in interventional cardiology? New trial data comparing OCT and IVUS as imaging options in PCI has reignited excitement around the potential benefits of OCT in cardiology. Drs Niels Holm and Lene Andreasen bring us up to speed with the latest evidence, and explore whether we should expect to see this technology in use in our clinics in the future. For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates...
Oct 16, 2023•19 min•Ep. 6
Emerging biomarkers in thyroid and non-small cell lung cancers Next-generation sequencing is a powerful tool that can identify mutations or fusions in a wide range of cancers, enabling physicians to provide targeted therapy to patients and improve outcomes. In this podcast, Professor Andrew Beggs discusses practical aspects of this technique from the clinical viewpoint. This content is intended only for healthcare providers and was made possible by educational funding provided by Illumina, Inc.,...
Sep 21, 2023•25 min•Ep. 5
A new era for managing Parkinson’s disease? STEM-PD, the first in-human safety trial of stem cell therapy for Parkinson’s disease, began this year and marks a huge step forward for this type of treatment. We talk to Prof. Malin Parmar about why stem cell therapy is such a good option for patients with Parkinson’s disease and get an update on the current status of the trial. For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and registe...
Aug 14, 2023•18 min•Ep. 4
Why is it so difficult to diagnose and manage? Resistant hypertension is a difficult to treat and often misunderstood phenomenon that continues to frustrate cardiologists. In this episode, Professors Morris Brown and Bryan Williams debate the causes of resistant hypertension and explore novel treatment options. For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates....
Jul 07, 2023•23 min•Ep. 3
An exciting option for treating metastatic prostate cancer? PARP inhibitors are an emerging treatment option for metastatic castration-resistant prostate cancer and the 2023 ASCO Genitourinary Cancers Symposium saw initial analyses and updates from several trials of these agents that help to address some gaps in the current understanding. In this episode, Dr. Elena Castro takes us through the latest evidence for PARP inhibitors and their combinations in this setting. For more on how Springer Med...
Jun 01, 2023•23 min•Ep. 2
How do doctors learn in the digital age? Doctors are required to stay continually up to date with all the latest clinical advances in their field. We discuss the challenges of that, the opportunities offered by new digital tools, and how medical education providers can best help. For more on how Springer Medicine can tailor medical education to meet your needs, head to SpringerMedicine.com and register for updates.
Apr 18, 2023•31 min•Ep. 1
An introduction to Springer Medicine, a new European medical education platform, and to Medicine Matters, the platform's podcast. Better informed doctors make better decisions. Which is why we are launching Springer Medicine, a pan-European, English-language, medical education platform. Our mission is to educate our doctors on the latest clinical advances, so you can offer your patients the best possible care. In this episode, Dr. Jane Godsland & Dr. Erik Heintz introduce the new platform an...
Feb 20, 2023•12 min•Ep. 1
